L&C Bio Co. Ltd Asset Resilience Ratio
L&C Bio Co. Ltd asset resilience ratio. L&C Bio Co. Ltd (290650) has an Asset Resilience Ratio of 2.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See L&C Bio Co. Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of L&C Bio Co. Ltd (2016–2024)
Asset resilience ratio of L&C Bio Co. Ltd from 2016 to 2024. This chart shows how L&C Bio Co. Ltd's Asset Resilience Ratio has changed over time. Read 290650 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down L&C Bio Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 290650 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩10.66 Billion | 2.14% |
| Total Liquid Assets | ₩10.66 Billion | 2.14% |
Asset Resilience Insights
- Limited Liquidity: L&C Bio Co. Ltd maintains only 2.14% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
L&C Bio Co. Ltd Industry Peers by Asset Resilience Ratio
Compare L&C Bio Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
L&C Bio Co. Ltd Asset Resilience Ratio by Year (2016–2024)
L&C Bio Co. Ltd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for L&C Bio Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.08% | ₩24.14 Billion ≈ $16.36 Million |
₩475.60 Billion ≈ $322.31 Million |
-17.50pp |
| 2023-12-31 | 22.57% | ₩59.19 Billion ≈ $40.11 Million |
₩262.23 Billion ≈ $177.71 Million |
+16.41pp |
| 2022-12-31 | 6.17% | ₩12.32 Billion ≈ $8.35 Million |
₩199.73 Billion ≈ $135.35 Million |
-12.10pp |
| 2021-12-31 | 18.27% | ₩19.62 Billion ≈ $13.30 Million |
₩107.40 Billion ≈ $72.78 Million |
-15.67pp |
| 2020-12-31 | 33.94% | ₩27.34 Billion ≈ $18.53 Million |
₩80.58 Billion ≈ $54.60 Million |
-9.72pp |
| 2019-12-31 | 43.66% | ₩28.91 Billion ≈ $19.59 Million |
₩66.23 Billion ≈ $44.88 Million |
-20.10pp |
| 2018-12-31 | 63.76% | ₩36.58 Billion ≈ $24.79 Million |
₩57.38 Billion ≈ $38.88 Million |
+31.65pp |
| 2017-12-31 | 32.11% | ₩6.58 Billion ≈ $4.46 Million |
₩20.49 Billion ≈ $13.89 Million |
+7.35pp |
| 2016-12-31 | 24.76% | ₩3.88 Billion ≈ $2.63 Million |
₩15.66 Billion ≈ $10.61 Million |
-- |
About L&C Bio Co. Ltd
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products. L&C Bio Co., Ltd was founded in 2011 and is headquartered in Seongnam-si, South Korea.